BlackRock
SGMT icon

BlackRock’s Sagimet Biosciences SGMT Stock Holding History

BlackRock’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.8M Buy
6,575,788
+5,775,845
+722% +$39.3M ﹤0.01% 2664
2026
Q1 		$4.18M Sell
799,943
-14,010
-2% -$78.1K ﹤0.01% 3898
2025
Q4 		$4.82M Buy
813,953
+201,236
+33% +$1.45M ﹤0.01% 3851
2025
Q3 		$4.2M Buy
612,717
+129,634
+27% +$1.05M ﹤0.01% 3846
2025
Q2 		$3.68M Sell
483,083
-487,741
-50% -$2.06M ﹤0.01% 3888
2025
Q1 		$3.16M Sell
970,824
-7,899
-0.8% -$33.1K ﹤0.01% 3831
2024
Q4 		$4.4M Buy
978,723
+26,132
+3% +$132K ﹤0.01% 3776
2024
Q3 		$2.64M Buy
952,591
+48,508
+5% +$150K ﹤0.01% 3915
2024
Q2 		$3.09M Sell
904,083
-1,121,528
-55% -$5.14M ﹤0.01% 3850
2024
Q1 		$11M Buy
2,025,611
+1,638,210
+423% +$11.8M ﹤0.01% 3305
2023
Q4 		$2.1M Buy
387,401
+63,993
+20% +$302K ﹤0.01% 4022
2023
Q3 		$2.85M Buy
+323,408
New +$4.31M ﹤0.01% 3877

Other funds holding SGMT

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock's SGMT Position: Q2 2026 in Review

BlackRock increased its Sagimet Biosciences (SGMT) stake by 722% in Q2 2026, buying an estimated $39.3M and bringing the position to 6,575,788 shares worth $50.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2664.

BlackRock first reported a position in SGMT in Q3 2023 and has held it in 12 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • BlackRock held 6,575,788 shares of Sagimet Biosciences worth $50.8M as of Q2 2026.
  • BlackRock bought 5,775,845 Sagimet Biosciences shares in Q2 2026, an estimated $39.3M.
  • Sagimet Biosciences made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2664 holding.
  • BlackRock first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 12 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.